The Trump administration is reportedly drafting a stopgap measure that would let some compounding pharmacies sell certain peptides on a temporary basis while federal health officials work out permanent rules, according to an October 7, 2026 report from The Washington Post, which cited two unnamed people familiar with the matter. The plan has not been announced, is not finalized, and the Department of Health and Human Services (HHS) declined to comment when asked by the Post.
What's Being Reported
Per the Post's sourcing, officials are weighing an interim approach that would give state-licensed compounding pharmacies more room to prepare specified peptides for patients with a prescription, rather than waiting for the FDA's formal rulemaking process to run its course. The report does not specify which peptides would be covered, and the Post notes the timing of any such move is unclear and could change. This is a reported deliberation, not a published policy, and nothing described here has taken effect.
The Backdrop: A Year of Back-and-Forth on Peptide Compounding
This would not happen in a vacuum. The FDA has spent much of 2026 sorting out which peptides pharmacies may legally compound under Section 503A of the Food, Drug, and Cosmetic Act. In July, the agency's Pharmacy Compounding Advisory Committee (PCAC) voted on seven peptides proposed for removal from the FDA's "Category 2" safety-concern list, recommending six for further consideration, as this site reported at the time, while voting against emideltide, a compound proposed for opioid withdrawal and insomnia uses. A PCAC recommendation, as this site has also explained elsewhere, is not a rule change by itself; the FDA still has to act on it. Separately, and in the opposite direction, the FDA proposed in April to permanently exclude semaglutide, tirzepatide, and liraglutide from the bulk substances list that allows compounding of copies of brand-name GLP-1 drugs. The peptide-compounding landscape has effectively been moving on two different tracks at once: tighter on the major GLP-1 drugs, more permissive on a set of smaller, less-studied peptides.
Who's Pushing for Broader Access
Trade groups representing compounding pharmacies have been asking the FDA for exactly this kind of interim flexibility. The Alliance for Pharmacy Compounding has specifically requested enforcement discretion that would let state-licensed pharmacies prepare these peptides for patients with a valid prescription while the rulemaking process continues, arguing that regulated compounding is preferable to the unregulated "research chemical" market peptides are often sold through today. The group says it supports pairing that access with enhanced patient disclosures, adverse event reporting, and ongoing data collection, rather than an unconditional opening of the market.
What FDA Scientists and Safety Groups Are Saying
The caution on the other side comes largely from inside the FDA itself. Agency scientists have said there isn't enough safety and effectiveness evidence behind several of these peptides to support routine clinical use, and that view underlies why compounds like BPC-157 and TB-500 landed on the Category 2 list in the first place. Patient-safety organizations have separately flagged the same underlying problem: for most of these compounds, rigorous human trial data, the kind this site covers in its research section on clinical trial phases and evidence quality, remains thin to nonexistent, with most of the existing research still confined to animal and cell-culture studies.
What Hasn't Been Decided
A lot. The Post's report describes people "familiar with the matter," not an official announcement, and HHS would not confirm or deny it. It isn't known which peptides, if any, would be named in a final version of this kind of measure, whether it would apply broadly or compound-by-compound, or when, if ever, it would be formally proposed. The FDA is also not required to follow its own advisory committee's recommendations, and formal rulemaking, which this kind of permanent change would ultimately require, is a slower and more public process than an internal policy memo.
The Bottom Line
Nothing has changed yet. No peptide currently outside the FDA's approved-drug list or its permitted compounding categories has become legal to compound or sell as a result of this reporting, and the compounds most commonly discussed in this context, including BPC-157 and TB-500, remain unapproved for any human use today. Anyone currently using, or considering, a compounded or research-labeled peptide should know that its safety and effectiveness have not been established through the clinical trial process the FDA requires for approved drugs, and should talk to a licensed physician before starting, stopping, or changing any treatment. This site will track the story as the administration's plans, if any, become official.